Prostatic cancer marker lncRNA MALAT-1 and application thereof

A prostate cancer and sequence technology, applied in the field of molecular biology, can solve problems such as elevated PSA

Inactive Publication Date: 2015-04-08
SHANGHAI CHANGHAI HOSPITAL
View PDF1 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, PSA is a prostate-specific rather than PCa-specific molecular marker, such as prostatitis, benign prostatic hyperplasia, etc. can cause the increase of PSA
In the "diagnostic gray ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prostatic cancer marker lncRNA MALAT-1 and application thereof
  • Prostatic cancer marker lncRNA MALAT-1 and application thereof
  • Prostatic cancer marker lncRNA MALAT-1 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Summary of clinical specimen information

[0101] In this study, 536 consecutive clinical cases were selected, of which 29 cases were excluded due to insufficient RNA isolation in urine sediment, and 73 cases were excluded due to insufficient collection of prostate cells in urine sediment. Therefore, the final cases of this study The number is 434 cases, of which 218 cases were in the discovery group and 216 cases in the verification group. The clinical information of all cases is summarized in Table 1. It can be seen from Table 1 that in the overall population of the discovery group, PCa-related risk factors (age, total PSA, prostate volume, PSA free ratio, and digital rectal examination) were significantly higher in the tumor group than in the negative biopsy group. However, in the "diagnostic gray zone" of PSA, serum total PSA could not distinguish the tumor group from the biopsy-negative group. Thereafter, the present inventors also obtained the same conclusion in...

Embodiment 2

[0103] The urine MALAT-1 score can clearly distinguish the tumor group from the biopsy-negative group and is highly correlated with the detection rate of PCa

[0104] In order to study whether the urine MALAT-1 score can be used as an effective PCa molecular marker, the inventors of this study detected the urine MALAT-1 score in the discovery group and the verification group, and made further statistical analysis. The study found that whether in the general population or in the PSA "diagnostic gray area" population, the expression of urine MALAT-1 score in tumor cases was significantly higher than that in negative cases, such as figure 2 The difference in the expression of urine MALAT-1 score between the tumor group and the biopsy-negative group, (A) the overall population of the discovery group, (B) the PSA "diagnostic gray area" population of the discovery group, (C) the overall population of the verification group , (D) Validation group PSA "diagnostic gray zone" populatio...

Embodiment 3

[0107] Logistic regression analysis of the diagnostic performance of urine MALAT-1 score for PCa

[0108] The inventors established univariate and multivariate logistic regression models, and proved that the urine MALAT-1 score and other risk factors are independent predictors of PCa in the general population, but total PSA cannot be the predictor of PCa in the PSA "diagnostic gray zone" population. Independent predictors of PCa, see Table 2, Table 3 and Figure 6 The area under the receiver operating curve shown was used to analyze the diagnostic performance of urine MALAT-1 score and other risk factors for PCa.

[0109] In the univariate logistic regression model, the diagnostic efficiency of urine MALAT-1 score for PCa in the general population was not statistically significant compared with total PSA, but it was significantly better than total PSA in the PSA "diagnostic gray area" population, see Figure 4 A. Figure 4C and Supplementary Table 2. At the same time, no mat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a long non-coding RNA (lncRNA) MALAT-1, and application thereof as a prostatic cancer marker and application thereof to preparation of chips, preparations or kits for detection of prostatic cancer.

Description

technical field [0001] The invention belongs to the field of molecular biology, in particular, the invention relates to urine long-chain non-coding lncRNA MALAT-1 and its application as a prostate cancer marker. Background technique [0002] Prostate cancer (PCa) is a malignant tumor that seriously threatens men's health. Its morbidity and mortality peak at around 70 years old, accounting for the second highest cancer incidence rate and the sixth highest mortality rate in the world. The incidence of PCa in my country has been on a significant upward trend in recent years. In Beijing, Shanghai, Guangzhou and other medically and economically developed cities, the incidence of PCa has already ranked among the top ten common tumors in the local area. Data from the Shanghai Center for Disease Control further show that the incidence of PCa has leapt to the top of male genitourinary malignant tumors since 2002, rising from 2.6 / 100,000 in 1990 to 32.23 / 100,000 in 2009, ranking firs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/113C12N15/11C12N15/63C12Q1/68C40B40/06
Inventor 孙颖浩任善成王富博
Owner SHANGHAI CHANGHAI HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap